Infections à Vibrio : Questions médicales fréquentes
Nom anglais: Vibrio Infections
Descriptor UI:D014735
Tree Number:C01.150.252.400.959
Termes MeSH sélectionnés :
Scleroderma, Systemic
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Infections à Vibrio : Questions médicales les plus fréquentes",
"headline": "Infections à Vibrio : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Infections à Vibrio : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-04",
"dateModified": "2025-02-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Infections à Vibrio"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Infections bactériennes à Gram négatif",
"url": "https://questionsmedicales.fr/mesh/D016905",
"about": {
"@type": "MedicalCondition",
"name": "Infections bactériennes à Gram négatif",
"code": {
"@type": "MedicalCode",
"code": "D016905",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.150.252.400"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Choléra",
"alternateName": "Cholera",
"url": "https://questionsmedicales.fr/mesh/D002771",
"about": {
"@type": "MedicalCondition",
"name": "Choléra",
"code": {
"@type": "MedicalCode",
"code": "D002771",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.150.252.400.959.347"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Infections à Vibrio",
"alternateName": "Vibrio Infections",
"code": {
"@type": "MedicalCode",
"code": "D014735",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Bo Peng",
"url": "https://questionsmedicales.fr/author/Bo%20Peng",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Biocontrol, Guangdong Key Laboratory of Pharmaceutical Functional Genes, School of Life Sciences, Sun Yat-sen University, Guangzhou, 510275, China. Electronic address: pengb26@mail.sysu.edu.cn."
}
},
{
"@type": "Person",
"name": "Fei Li",
"url": "https://questionsmedicales.fr/author/Fei%20Li",
"affiliation": {
"@type": "Organization",
"name": "College of Life Science and Technology, Beijing University of Chemical Technology, China; Clinical Laboratory center, Taian City Central Hospital, Taian 271000, China."
}
},
{
"@type": "Person",
"name": "Yigang Tong",
"url": "https://questionsmedicales.fr/author/Yigang%20Tong",
"affiliation": {
"@type": "Organization",
"name": "College of Life Science and Technology, Beijing University of Chemical Technology, China. Electronic address: tong.yigang@gmail.com."
}
},
{
"@type": "Person",
"name": "Jaime Martinez-Urtaza",
"url": "https://questionsmedicales.fr/author/Jaime%20Martinez-Urtaza",
"affiliation": {
"@type": "Organization",
"name": "Department de Genetica I de Microbiologia, Facultat de Biociencies, Universitat Autonoma de Barcelona, Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "C H Ding",
"url": "https://questionsmedicales.fr/author/C%20H%20Ding",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Microbiology & Immunology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Spatial Transcriptomics Identifies Cellular and Molecular Characteristics of Scleroderma Skin Lesions: Pilot Study in Juvenile Scleroderma.",
"datePublished": "2024-08-23",
"url": "https://questionsmedicales.fr/article/39273131",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms25179182"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pulmonary Hypertension in Scleroderma- Evaluation and Management.",
"datePublished": "2022-09-24",
"url": "https://questionsmedicales.fr/article/36163292",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.disamonth.2022.101468"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.",
"datePublished": "2022-10-14",
"url": "https://questionsmedicales.fr/article/36244404",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.chest.2022.09.044"
}
},
{
"@type": "ScholarlyArticle",
"name": "Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE).",
"datePublished": "2022-08-02",
"url": "https://questionsmedicales.fr/article/35931315",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.autrev.2022.103167"
}
},
{
"@type": "ScholarlyArticle",
"name": "Scleroderma autoantibodies in guiding monitoring and treatment decisions.",
"datePublished": "2022-08-29",
"url": "https://questionsmedicales.fr/article/36082759",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/BOR.0000000000000904"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Infection",
"item": "https://questionsmedicales.fr/mesh/D007239"
},
{
"@type": "ListItem",
"position": 3,
"name": "Infections bactériennes et mycoses",
"item": "https://questionsmedicales.fr/mesh/D001423"
},
{
"@type": "ListItem",
"position": 4,
"name": "Infections bactériennes",
"item": "https://questionsmedicales.fr/mesh/D001424"
},
{
"@type": "ListItem",
"position": 5,
"name": "Infections bactériennes à Gram négatif",
"item": "https://questionsmedicales.fr/mesh/D016905"
},
{
"@type": "ListItem",
"position": 6,
"name": "Infections à Vibrio",
"item": "https://questionsmedicales.fr/mesh/D014735"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Infections à Vibrio - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Infections à Vibrio",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Infections à Vibrio",
"description": "Comment diagnostique-t-on une infection à Vibrio ?\nQuels tests sont utilisés pour identifier Vibrio ?\nLes symptômes aident-ils au diagnostic ?\nPeut-on diagnostiquer sans culture ?\nLes antécédents de voyage sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D014735?mesh_terms=Scleroderma,+Systemic&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Infections à Vibrio",
"description": "Quels sont les symptômes courants d'une infection à Vibrio ?\nLes infections à Vibrio causent-elles des éruptions cutanées ?\nY a-t-il des symptômes graves à surveiller ?\nLes symptômes varient-ils selon la souche de Vibrio ?\nLes symptômes apparaissent-ils rapidement ?",
"url": "https://questionsmedicales.fr/mesh/D014735?mesh_terms=Scleroderma,+Systemic&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Infections à Vibrio",
"description": "Comment prévenir les infections à Vibrio ?\nLa cuisson des fruits de mer est-elle suffisante ?\nL'eau potable est-elle un risque ?\nLes voyages en zones à risque nécessitent-ils des précautions ?\nLes personnes à risque doivent-elles être plus prudentes ?",
"url": "https://questionsmedicales.fr/mesh/D014735?mesh_terms=Scleroderma,+Systemic&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Infections à Vibrio",
"description": "Quel est le traitement principal pour les infections à Vibrio ?\nLes antibiotiques sont-ils toujours nécessaires ?\nComment la déshydratation est-elle traitée ?\nY a-t-il des traitements préventifs ?\nLes probiotiques aident-ils dans le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D014735?mesh_terms=Scleroderma,+Systemic&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Infections à Vibrio",
"description": "Quelles sont les complications possibles des infections à Vibrio ?\nLes infections cutanées peuvent-elles s'aggraver ?\nY a-t-il un risque de septicémie ?\nLes complications sont-elles fréquentes ?\nComment gérer les complications ?",
"url": "https://questionsmedicales.fr/mesh/D014735?mesh_terms=Scleroderma,+Systemic&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Infections à Vibrio",
"description": "Quels sont les principaux facteurs de risque ?\nLes personnes âgées sont-elles plus à risque ?\nLes maladies chroniques augmentent-elles le risque ?\nLa saison influence-t-elle le risque d'infection ?\nLes voyages à l'étranger augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D014735?mesh_terms=Scleroderma,+Systemic&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une infection à Vibrio ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des cultures de selles et des tests sérologiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour identifier Vibrio ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cultures bactériennes et des tests PCR sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les symptômes aident-ils au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes cliniques orientent le diagnostic, mais des tests sont nécessaires."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer sans culture ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des méthodes moléculaires comme la PCR peuvent être utilisées sans culture."
}
},
{
"@type": "Question",
"name": "Les antécédents de voyage sont-ils importants ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de consommation de fruits de mer ou de baignade en eau contaminée sont cruciaux."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants d'une infection à Vibrio ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent diarrhée, vomissements, douleurs abdominales et fièvre."
}
},
{
"@type": "Question",
"name": "Les infections à Vibrio causent-elles des éruptions cutanées ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines souches peuvent provoquer des infections cutanées, surtout après exposition à l'eau."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes graves à surveiller ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes graves incluent déshydratation sévère et choc septique, nécessitant une attention médicale."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon la souche de Vibrio ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon la souche, comme Vibrio cholerae ou Vibrio parahaemolyticus."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils rapidement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent apparaître rapidement, souvent dans les 24 heures suivant l'infection."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections à Vibrio ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez de consommer des fruits de mer crus et lavez-vous les mains régulièrement."
}
},
{
"@type": "Question",
"name": "La cuisson des fruits de mer est-elle suffisante ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, cuire les fruits de mer à des températures appropriées tue les bactéries Vibrio."
}
},
{
"@type": "Question",
"name": "L'eau potable est-elle un risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'eau non traitée peut être contaminée, évitez de boire de l'eau non purifiée."
}
},
{
"@type": "Question",
"name": "Les voyages en zones à risque nécessitent-ils des précautions ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est conseillé de prendre des précautions alimentaires et d'hygiène lors de voyages."
}
},
{
"@type": "Question",
"name": "Les personnes à risque doivent-elles être plus prudentes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées doivent éviter les fruits de mer crus et les eaux contaminées."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour les infections à Vibrio ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la réhydratation, souvent accompagné d'antibiotiques si nécessaire."
}
},
{
"@type": "Question",
"name": "Les antibiotiques sont-ils toujours nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les antibiotiques ne sont pas toujours nécessaires, surtout pour les infections légères."
}
},
{
"@type": "Question",
"name": "Comment la déshydratation est-elle traitée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La déshydratation est traitée par des solutions de réhydratation orale ou intraveineuse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements préventifs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccins existent pour certaines souches, mais leur utilisation est limitée."
}
},
{
"@type": "Question",
"name": "Les probiotiques aident-ils dans le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les probiotiques peuvent aider à restaurer la flore intestinale, mais leur efficacité varie."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des infections à Vibrio ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la déshydratation sévère, le choc septique et des infections systémiques."
}
},
{
"@type": "Question",
"name": "Les infections cutanées peuvent-elles s'aggraver ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections cutanées peuvent s'aggraver et nécessiter des soins médicaux urgents."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de septicémie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines souches de Vibrio peuvent provoquer une septicémie, surtout chez les personnes vulnérables."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir, surtout chez les personnes à risque."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications nécessitent une prise en charge médicale rapide, souvent en milieu hospitalier."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent la consommation de fruits de mer crus et l'exposition à des eaux contaminées."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées et immunodéprimées sont plus susceptibles de développer des infections graves."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies chroniques comme le diabète augmentent le risque d'infections à Vibrio."
}
},
{
"@type": "Question",
"name": "La saison influence-t-elle le risque d'infection ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'infection augmente pendant les mois chauds, favorisant la prolifération de Vibrio."
}
},
{
"@type": "Question",
"name": "Les voyages à l'étranger augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des régions où Vibrio est endémique augmente le risque d'infection."
}
}
]
}
]
}
Juvenile localized and systemic scleroderma are rare autoimmune diseases which cause significant disability and morbidity in children. The mechanisms driving juvenile scleroderma remain unclear, neces...
Pulmonary Arterial Hypertension (PAH) is a clinical syndrome consisting of physiologic/hemodynamic criteria that are a consequence of several etiologies. Systemic Sclerosis (SSc), one of the most comm...
Enrichment strategies from clinical trials for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) have not been tested in a real-life cohort....
Do enrichment strategies for progressive ILD impact efficacy, representativeness, and feasibility in patients with SSc-ILD from the European Scleroderma Trials and Research (EUSTAR) database?...
We applied the inclusion criteria of major recent SSc-ILD trials (Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis [focuSSced], Scleroderma Lung Study II [SLS II...
In total, 2,258 patients with SSc-ILD were included: 31.2% of the patients met SENSCIS criteria; 5.8% of the patients met SLS II criteria; 1.6% of the patients met focuSSced criteria, and 67.7% (1,529...
The application of enrichment criteria from previous clinical trials showed enrichment for progression with variable success, which led to selected patient populations reducing feasibility of recruitm...
Patients with systemic sclerosis (SSc) are at increased risk of cancer, a growing cause of non-SSc-related death among these patients. We analyzed the increased cancer risk among Spanish patients with...
Spanish Scleroderma Registry data were analyzed to determine the demographic characteristics of patients with SSc, and logistic regression was used to identify cancer risk factors. SIRs with 95% confi...
Of 1930 patients with SSc, 206 had cancer, most commonly breast, lung, hematological, and colorectal cancers. Patients with SSc had increased risks of overall cancer (SIR 1.48, 95% CI 1.36-1.60; P < 0...
Spanish patients with SSc had an increased cancer risk compared with the general population. Some characteristics, including specific autoantibodies, may be related to this increased risk....
One of the key clinical challenges of systemic sclerosis (SSc) is diversity in clinical presentation, organ involvement and disease progression. Antinuclear autoantibodies (ANA) are central to the dia...
There has been further development in delineating clinical patterns in ANA, genetic susceptibility and antigen triggers predisposing to ANA subtypes. Sub-group analysis of recent clinical trials shows...
ANA subtyping is likely to be firmly embedded into future classification systems. Beyond informing current management and monitoring of scleroderma patients, ANA subsets have implication on future res...
The mechanisms of systemic autoimmune diseases (ADs) are still not clearly understood. Understanding the etiology of systemic ADs and identifying new therapeutic targets require a systems science appr...
People with systemic sclerosis (SSc) are vulnerable in COVID-19 and face challenges related to shifting COVID-19 risk and protective restrictions. We evaluated mental health symptom trajectories in pe...
The longitudinal Scleroderma Patient-centred Intervention Network (SPIN) COVID-19 cohort was launched in April 2020 and included participants from the ongoing SPIN Cohort and external enrolees. Analys...
Anxiety symptoms increased in early 2020 but returned to pre-COVID-19 levels by mid-2020 and remained stable through March 2022. Depression symptoms did not initially change but were slightly lower by...
People with SSc continue to face COVID-19 challenges related to ongoing risk, the opening of societies, and removal of protective restrictions. People with SSc, in aggregate, appear to be weathering t...
Systemic sclerosis (SSc) is a rare auto-immune disease, affecting principally women between 40 and 60 years old. It is caracterised by a cutaneous and visceral fibrosis, an alteration of the microvasc...
We have analysed the data of a retrospective and bicentrique cohort, from the internal medicine unit of Hôpital Nord in Marseille and from the internal medicine unit of the Hôpital Sainte-Anne in Toul...
The cohort included 151 patients including 134 limited cutaneous SSc. Fifty-two (34.4%) patients presented at least one associated auto-immune or inflammatory disease. The association of two connectiv...
SSc is often associated with other autoimmune diseases. This interrelation between associated pathologies and SSc, modifying sometimes the evolution of SSc, enhances the need of a personalized follow-...
Systemic sclerosis (SSc) represents extremely rare disease with majority of data coming from adults. Studies comparing juvenile- (jSSc) and adult-onset (aSSc) patients are limited. We aimed to compare...
A retrospective study among pediatric and adult Scl patients has been performed. Demographic characteristics, clinical features, autoantibody profiles, and treatment data were retrieved from the datab...
A total of 158 adults and 58 juvenile Scl patients were identified. The mean age at the disease onset was 37±14.7 vs. 8.8 ± 4.1 years, mean age at diagnosis 42±15.2 vs. 10.4 ± 3.8 years and mean follo...
Juvenile and adult-onset Scl represent rarely seen conditions with different clinical phenotypes. Pediatric patients with LS are more commonly seen by pediatric rheumatologists, in contrary to adults....
Systemic sclerosis (SSc), also known as scleroderma, is a chronic autoimmune connective tissue disease and is associated with a significant economic burden resulting from health care utilization costs...